Literature DB >> 19830694

EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms.

Massod Rahimi1, Jessica George1, Careen Tang1.   

Abstract

The expression of the potent, constitutively activated EGFR variant, EGFRvIII, has been linked to breast cancer metastasis, but the mechanisms of EGFRvIII and CXCR4 crosstalk, which may facilitate breast cancer invasion, have never been explored. Here we report that CXCR4 expression is increased in breast cancer cells expressing EGFRvIII regardless of the ER/PgR status of the cells. Treatment of EGFRvIII-expressing breast cancer cells with the tyrosine kinase inhibitor, AG1478, reverses CXCR4 expression back to levels expressed in parental cells. In addition, expressing EGFRvIII enhances CXCL12/CXCR4-mediated invasion, which can be inhibited by CXCR4 inhibitors. Surprisingly, CXCR4 mRNA and its transcriptional regulator, HIF-1alpha, are up-regulated only in ER+/PgR+ estrogen-dependent EGFRvIII-expressing breast cancer cells, but not in ER-/PgR- or estrogen-independent cell lines, suggesting that HIF-1alpha and hormone receptor-mediated actions may have a role in the transcriptional regulation of CXCR4. We also demonstrate that p38 MAPK is one of the major down-stream signaling molecules responsible for EGFRvIII/CXCR4-mediated invasion as p38 MAPK activity was induced by CXCL12 stimulation under both normoxic and hypoxic conditions. More interestingly, inhibition of p38 MAPK activity significantly reduced CXCR4 expression and inhibited the invasive potential of EGFRvIII-expressing breast cancer cells, suggesting an essential role for p38 MAPK in EGFRvIII/CXCR4 induced invasion. Furthermore, CXCR4 is regulated post-translationally through decreased expression of AIP4 and beta-arrestin 1/2, molecules involved in CXCR4 internalization, cellular trafficking and degradation. These results provide a plausible mechanism for EGFRvIII-mediated invasion and establish a functional link between EGFRvIII and CXCR4 signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19830694      PMCID: PMC2917067          DOI: 10.1002/ijc.24964

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

1.  CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.

Authors:  Neslihan Cabioglu; M Sertac Yazici; Banu Arun; Kristine R Broglio; Gabriel N Hortobagyi; Janet E Price; Aysegul Sahin
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.

Authors:  Ombretta Salvucci; Amélie Bouchard; Andrea Baccarelli; Jean Deschênes; Guido Sauter; Ronald Simon; Rosella Bianchi; Mark Basik
Journal:  Breast Cancer Res Treat       Date:  2005-12-13       Impact factor: 4.872

3.  Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.

Authors:  Neslihan Cabioglu; Aysegul Sahin; Michele Doucet; Ekrem Yavuz; Abdullah Igci; Engin O Yildirim; Esin Aktas; Sema Bilgic; Bayram Kiran; Gunnur Deniz; Janet E Price
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

4.  p38gamma mitogen-activated protein kinase integrates signaling crosstalk between Ras and estrogen receptor to increase breast cancer invasion.

Authors:  Xiaomei Qi; Jun Tang; Mathew Loesch; Nicole Pohl; Serhan Alkan; Guan Chen
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

5.  Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII.

Authors:  Wei Han; Tao Zhang; Hong Yu; John G Foulke; Careen K Tang
Journal:  Cancer Biol Ther       Date:  2006-10-26       Impact factor: 4.742

6.  Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients.

Authors:  Henriqueta A C Silva; Elsa Abraúl; Dulce Raimundo; Margarida F Dias; Carlos Marques; Carlos Guerra; Carlos F de Oliveira; Fernando J Regateiro
Journal:  Eur J Cancer       Date:  2006-09-07       Impact factor: 9.162

7.  CXCL12 induces tyrosine phosphorylation of cortactin, which plays a role in CXC chemokine receptor 4-mediated extracellular signal-regulated kinase activation and chemotaxis.

Authors:  Cherry Luo; Heng Pan; Marjelo Mines; Kurt Watson; Jingwu Zhang; Guo-Huang Fan
Journal:  J Biol Chem       Date:  2006-08-11       Impact factor: 5.157

8.  Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression.

Authors:  Xiang-Hong Peng; Prasanthi Karna; Zehong Cao; Bing-Hua Jiang; Muxiang Zhou; Lily Yang
Journal:  J Biol Chem       Date:  2006-07-17       Impact factor: 5.157

9.  CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation.

Authors:  Neslihan Cabioglu; Justin Summy; Claudia Miller; Nila U Parikh; Aysegul A Sahin; Sitki Tuzlali; Kevin Pumiglia; Gary E Gallick; Janet E Price
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

10.  Activation of p38 mitogen-activated protein kinase promotes epidermal growth factor receptor internalization.

Authors:  Silvia Vergarajauregui; Anitza San Miguel; Rosa Puertollano
Journal:  Traffic       Date:  2006-06       Impact factor: 6.215

View more
  12 in total

1.  CXCR4 suppression attenuates EGFRvIII-mediated invasion and induces p38 MAPK-dependent protein trafficking and degradation of EGFRvIII in breast cancer cells.

Authors:  Massod Rahimi; Theodore A Toth; Careen K Tang
Journal:  Cancer Lett       Date:  2011-03-30       Impact factor: 8.679

2.  The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis.

Authors:  Liping Qiu; Yuanyuan Xu; Hui Xu; Biyun Yu
Journal:  BMC Cancer       Date:  2022-06-21       Impact factor: 4.638

3.  The Role of chemokine receptor CXCR4 in breast cancer metastasis.

Authors:  Debarati Mukherjee; Jihe Zhao
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

Review 4.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

5.  Interaction between CXCR4 and EGFR and downstream PI3K/AKT pathway in lung adenocarcinoma A549 cells and transplanted tumor in nude mice.

Authors:  Juan Wu; Ying Liu; Yaling Ma; Rui Wang; Xiaokun Ji; Yan Zhang; Yun Du
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

Review 6.  Post-Translational Modifications of G Protein-Coupled Receptors Control Cellular Signaling Dynamics in Space and Time.

Authors:  Anand Patwardhan; Norton Cheng; JoAnn Trejo
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 7.  CXCR4 in breast cancer: oncogenic role and therapeutic targeting.

Authors:  Chao Xu; Hong Zhao; Haitao Chen; Qinghua Yao
Journal:  Drug Des Devel Ther       Date:  2015-08-28       Impact factor: 4.162

8.  Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance.

Authors:  Kwang-Yu Chang; Shan-Yin Tsai; Shang-Hung Chen; Hsiao-Hui Tsou; Chia-Jui Yen; Ko-Jiunn Liu; Hsun-Lang Fang; Hung-Chang Wu; Bin-Fay Chuang; Shao-Wen Chou; Careen K Tang; Shyun-Yeu Liu; Pei-Jung Lu; Ching-Yu Yen; Jang-Yang Chang
Journal:  J Biomed Sci       Date:  2013-06-27       Impact factor: 8.410

9.  COUP-TFI modifies CXCL12 and CXCR4 expression by activating EGF signaling and stimulates breast cancer cell migration.

Authors:  Antoine Boudot; Gwenneg Kerdivel; Sylvain Lecomte; Gilles Flouriot; Mireille Desille; Florence Godey; Jean Leveque; Patrick Tas; Yves Le Dréan; Farzad Pakdel
Journal:  BMC Cancer       Date:  2014-06-06       Impact factor: 4.430

10.  The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo.

Authors:  Xiaoyang Ling; Erika Spaeth; Ye Chen; Yuexi Shi; Weiguo Zhang; Wendy Schober; Numsen Hail; Marina Konopleva; Michael Andreeff
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.